Dillon & Associates’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $311K | Sell |
2,031
-171
| -8% | -$26.2K | 0.04% | 65 |
|
|
2025
Q4 | $304K | Sell |
2,202
-25
| -1% | -$3.27K | 0.04% | 67 |
|
|
2025
Q3 | $285K | Sell |
2,227
-50
| -2% | -$6.1K | 0.04% | 69 |
|
|
2025
Q2 | $276K | Sell |
2,277
-784
| -26% | -$88.4K | 0.04% | 69 |
|
|
2025
Q1 | $340K | Sell |
3,061
-73
| -2% | -$7.77K | 0.05% | 66 |
|
|
2024
Q4 | $304K | Sell |
3,134
-100
| -3% | -$10.7K | 0.04% | 72 |
|
|
2024
Q3 | $372K | Sell |
3,234
-1,815
| -36% | -$206K | 0.05% | 68 |
|
|
2024
Q2 | $535K | Sell |
5,049
-274
| -5% | -$27.5K | 0.08% | 63 |
|
|
2024
Q1 | $516K | Sell |
5,323
-200
| -4% | -$20.5K | 0.08% | 62 |
|
|
2023
Q4 | $558K | Sell |
5,523
-402
| -7% | -$38.8K | 0.1% | 61 |
|
|
2023
Q3 | $604K | Sell |
5,925
-499
| -8% | -$50.7K | 0.12% | 59 |
|
|
2023
Q2 | $649K | Sell |
6,424
-80
| -1% | -$8K | 0.12% | 57 |
|
|
2023
Q1 | $598K | Sell |
6,504
-1,865
| -22% | -$163K | 0.12% | 59 |
|
|
2022
Q4 | $762K | Sell |
8,369
-80
| -0.9% | -$6.74K | 0.16% | 56 |
|
|
2022
Q3 | $642K | Hold |
8,449
| – | – | 0.15% | 56 |
|
|
2022
Q2 | $718K | Hold |
8,449
| – | – | 0.16% | 52 |
|
|
2022
Q1 | $744K | Hold |
8,449
| – | – | 0.14% | 51 |
|
|
2021
Q4 | $735K | Hold |
8,449
| – | – | 0.13% | 50 |
|
|
2021
Q3 | $693K | Hold |
8,449
| – | – | 0.13% | 49 |
|
|
2021
Q2 | $769K | Hold |
8,449
| – | – | 0.15% | 49 |
|
|
2021
Q1 | $718K | Sell |
8,449
-50
| -0.6% | -$4.49K | 0.15% | 49 |
|
|
2020
Q4 | $799K | Sell |
8,499
-190
| -2% | -$16.6K | 0.17% | 48 |
|
|
2020
Q3 | $756K | Hold |
8,689
| – | – | 0.18% | 50 |
|
|
2020
Q2 | $756K | Hold |
8,689
| – | – | 0.2% | 48 |
|
|
2020
Q1 | $712K | Sell |
8,689
-250
| -3% | -$22.3K | 0.24% | 47 |
|
|
2019
Q4 | $849K | Buy |
8,939
+190
| +2% | +$17K | 0.24% | 45 |
|
|
2019
Q3 | $761K | Sell |
8,749
-13
| -0.1% | -$1.17K | 0.23% | 46 |
|
|
2019
Q2 | $797K | Sell |
8,762
-988
| -10% | -$83.6K | 0.25% | 48 |
|
|
2019
Q1 | $839K | Sell |
9,750
-391
| -4% | -$31.4K | 0.27% | 45 |
|
|
2018
Q4 | $781K | Hold |
10,141
| – | – | 0.3% | 43 |
|
|
2018
Q3 | $781K | Sell |
10,141
-28
| -0.3% | -$2.07K | 0.26% | 45 |
|
|
2018
Q2 | $693K | Sell |
10,169
-1,507
| -13% | -$104K | 0.26% | 44 |
|
|
2018
Q1 | $847K | Sell |
11,676
-279
| -2% | -$21.2K | 0.33% | 41 |
|
|
2017
Q4 | $900K | Hold |
11,955
| – | – | 0.34% | 43 |
|
|
2017
Q3 | $921K | Sell |
11,955
-27
| -0.2% | -$2.04K | 0.36% | 41 |
|
|
2017
Q2 | $891K | Sell |
11,982
-506
| -4% | -$35.9K | 0.37% | 42 |
|
|
2017
Q1 | $828K | Sell |
12,488
-89
| -0.7% | -$5.93K | 0.35% | 42 |
|
|
2016
Q4 | $823K | Sell |
12,577
-1,386
| -10% | -$89.9K | 0.37% | 45 |
|
|
2016
Q3 | $988K | Sell |
13,963
-2,567
| -16% | -$187K | 0.46% | 40 |
|
|
2016
Q2 | $1.23M | Sell |
16,530
-4,358
| -21% | -$301K | 0.56% | 38 |
|
|
2016
Q1 | $1.35M | Sell |
20,888
-1,016
| -5% | -$69.1K | 0.63% | 40 |
|
|
2015
Q4 | $1.69M | Sell |
21,904
-2,062
| -9% | -$164K | 0.82% | 33 |
|
|
2015
Q3 | $1.98M | Sell |
23,966
-95
| -0.4% | -$8.46K | 0.99% | 33 |
|
|
2015
Q2 | $2.11M | Buy |
24,061
+116
| +0.5% | +$10.6K | 1.03% | 30 |
|
|
2015
Q1 | $2.12M | Buy |
23,945
+474
| +2% | +$42K | 1.02% | 30 |
|
|
2014
Q4 | $1.96M | Buy |
23,471
+378
| +2% | +$31.3K | 0.95% | 30 |
|
|
2014
Q3 | $1.95M | Buy |
23,093
+423
| +2% | +$34.2K | 0.99% | 31 |
|
|
2014
Q2 | $1.85M | Sell |
22,670
-269
| -1% | -$21.2K | 0.95% | 32 |
|
|
2014
Q1 | $1.75M | Buy |
22,939
+118
| +0.5% | +$8.6K | 0.93% | 33 |
|
|
2013
Q4 | $1.64M | Sell |
22,821
-167
| -0.7% | -$11.6K | 0.88% | 34 |
|
|
2013
Q3 | $1.63M | Sell |
22,988
-399
| -2% | -$26.4K | 0.91% | 33 |
|
|
2013
Q2 | $1.49M | Buy |
+23,387
| New | +$1.52M | 0.95% | 35 |
|
Other funds holding NVS
Dillon & Associates's NVS Position: Q1 2026 in Review
Dillon & Associates reduced its Novartis (NVS) stake by 7.8% in Q1 2026, selling an estimated $26.2K and leaving 2,031 shares worth $311K. The position accounts for 0.04% of the portfolio, ranked #65.
Dillon & Associates first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.12M in Q1 2015. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Dillon & Associates held 2,031 shares of Novartis worth $311K as of Q1 2026.
- Dillon & Associates sold 171 Novartis shares in Q1 2026, an estimated $26.2K.
- Novartis made up 0.04% of Dillon & Associates's portfolio in Q1 2026, its #65 holding.
- Dillon & Associates first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- Dillon & Associates's Novartis position peaked at $2.12M in Q1 2015.
- 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.